CME Group Cl A saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 70 to 78.
This proprietary rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the top-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if CME Group Cl A can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
The stock, which is on the IBD Big Cap 20 list, is now considered extended and out of buy range after clearing a 223.80 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
In terms of fundamental health, the company has posted two quarters of increasing earnings growth. Sales gains have also risen during the same period.
CME Group Cl A holds the No. 1 rank among its peers in the Financial Services-Specialty industry group. Exodus Movement and Marex Group are also among the group's highest-rated stocks.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
